BOLD SEC Filings: 8-K, 10-Q, S-3 & 424B – Boundless Bio

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 9, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Boundless Bio, Inc. Amends Merger Agreement with Serapha Bio, Inc.

Aug 28, 2026

8-K

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

Jun 23, 2026

8-K

Boundless Bio, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 17, 2026

8-K

Boundless Bio Reports First Quarter 2026 Financial Results and KOMODO-1 Clinical Progress

May 8, 2026

8-K

Boundless Bio, Inc. Announces Early Termination of San Diego Office and Laboratory Lease

Apr 13, 2026

8-K

Boundless Bio Reports 2025 Financial Results and KOMODO-1 Clinical Trial Enrollment

Mar 9, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

OFFERING - OTHER

Nov 3, 2026

425

Form 425 - Prospectuses and communications, business combinations

Oct 26, 2026

425

Form 425 - Prospectuses and communications, business combinations

Oct 26, 2026

425

Form 425 - Prospectuses and communications, business combinations

Aug 28, 2026

425

Form 425 - Prospectuses and communications, business combinations

Jun 23, 2026

424B4

OFFERING | Shares amount: 6,250,000 | Share price: $16.00 | Offering amount: $100,000,000.00

Mar 28, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 30, 2026

S-4

Form S-4 - Registration of securities, business combinations

Oct 8, 2026

DRS

Form DRS - Draft Registration Statement

Aug 31, 2026

S-3

April 2025 SHELF & ATM

Apr 1, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 28, 2024

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Mar 22, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

Ownerships

TYPE

HEADLINE

FILED AT

TANG KEVIN (Reporting)

Nov 5, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 30, 2026

TANG KEVIN (Reporting)

Oct 29, 2026

TANG KEVIN (Reporting)

Oct 26, 2026

TANG KEVIN (Reporting)

Oct 20, 2026

S-4

Form S-4 - Registration of securities, business combinations

Oct 8, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 4, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 11, 2025

CORRESP

Form CORRESP - Correspondence

Apr 8, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 8, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jan 23, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 28, 2024

Boundless Bio, Inc. BOLD · SEC Filings